PD 169540
Latest Information Update: 19 Jul 2002
Price :
$50 *
At a glance
- Originator Pfizer
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 31 Jul 2000 Profile reviewed but no significant changes made
- 21 Jun 2000 Warner-Lambert has merged with Pfizer
- 24 Apr 1998 Preclinical development for Cancer in New Zealand (Unknown route)